Erratum: Concluding reply (Journal of Psychopharmacology (2012) 27:5 DOI: 10.1177/0269881112466185);The failure of the antidepressant drug discovery process is systemic

Journal of Psychopharmacology

Volumn 27, Issue 5, 2013, Pages 407-416

  Hendrie, Colin ^a   Pickles, Alasdair ^a   Stanford, S Clare ^b   Robinson, Emma ^b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Animal models; antidepressant; depression; drug discovery; MDD

Indexed keywords

ANTIDEPRESSANT AGENT;

ADAPTATION; BEHAVIOR; BRAIN THIRD VENTRICLE; DEPRESSION; DISEASE MODEL; DRUG DEVELOPMENT; DRUG RESEARCH; ETHOLOGY; EXPERIMENTAL ANIMAL; EXPERIMENTAL MOUSE; EXPERIMENTAL RAT; NONHUMAN; PRIORITY JOURNAL; REVIEW; SPECIES DIFFERENCE;

EID: 84876544546     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881115598057     Document Type: Erratum

References (120)

1. Barnett SA The Rat: A study in Behavior. Chicago: Aldine ; 1963 :
2. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961 ; 4: 561-571
3. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psych. 2000 ; 47: 351-354
4. Berry RJ. The natural history of the house mouse. Field Studies. 1970 ; 3: 219-226
5. Bielski RJ, Friedel RO. Prediction of tricyclic antidepressant response: A critical review. Arch Gen Psychiatry. 1976 ; 33: 1479-1489
6. Blazer DG Comprehensive Textbook of Psychiatry. Sadock BJ Sadock VA, ed. New York: Lippincott, Williams and Wilkins ; 2000: 1298-1308.
7. Blier P. The well of novel antidepressants: Running dry. J Psychiatry Neurosci. 2010 ; 35: 219-220
8. Borsini F. Models for depression in drug screening and preclinical studies: Future directions. World J Pharmacol. 2012 ; 1: 21-29
9. Brain PF. The physiology of population limitation in rodents - a review. Commun Behav Biol. 1971 ; 6: 115-123
10. Brown SL, Steinberg RL, van Praag HM Handbook of Depression and Anxiety: A Biological Approach. den Boer JA Sitsen JMA, ed. New York: Marcel Dekker ; 1994: 317-347.
11. Burt VK, Stein K. Epidemiology of depression throughout the female life cycle. J Clin Psychiatry. 2002 ; 63: 9-15
12. Castagné V, Moser P, Roux S, et al. Rodent models of depression: Forced swim and tail suspension behavioural despair tests in rats and mice. Curr Protoc Pharmacol. 2011 ;:
13. Chen J, Korostyshevsky D, Lee S, et al. Accumulation of an antidepressant in vesiculogenic membranes of yeast cells triggers autophagy. PLoS ONE. 2012 ; 7: e34024
14. Chermat R, Thierry B, Mico JA, et al. Adaptation of the tail suspension test to the rat. J Pharmacol. 1986 ; 17: 348-350
15. Chessin M, Dubnick B, Kramer ER, et al. Modifications of pharmacology of reserpine and serotonin by iproniazid. Federation Proc. 1956 ; 15: 409
16. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: A multiple-treatments meta-analysis. Lancet. 2009 ; 373: 746-758
17. Cole JC, Rodgers RJ. An ethological analysis of the effects of chlordiazepoxide and bretazenil (Ro16-6028) in the murine elevated plus-maze. Behav Pharmacol. 1993 ; 4: 573-580
18. Colman I, Naicker K, Zeng Y, et al. Predictors of long-term prognosis of depression.. CMAJ. 2011 ; 183: 1969-1976
19. Cryan JF, Holmes A. The ascent of mouse: Advances in modelling human depression and anxiety. Nat Rev Drug Discov. 2005 ; 4: 785-790
20. Cryan JF, Mombereau C. In search of a depressed mouse: Utility of models for studying depression-related behavior in genetically modified mice. Mol Psychiatry. 2004 ; 9: 326-3577
21. Cryan JF, Markou A, Lucki I. Assessing antidepressant activity in rodents: Recent developments and future needs. Trends Pharmacol Sci. 2002 ; 23: 238-245
22. Cryan JF, Mombereau C, Vassout A. The tail suspension test as a model for assessing antidepressant activity: Review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev. 2005 ; 29: 571-625
23. Detke MJ, Rickels M, Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology. 1995 ; 121: 66-72
24. Deussing JM. Animal models of depression. Drug Discov Today Dis Models. 2006 ; 3: 375-383
25. Dias AM, Santos AK, Takeuchi MY, et al. Depression across the species. Open Psychiatry J. 2009 ; 3: 33-38
26. Dixon AK. Ethological aspects of psychiatry. Schweiz Arch Neurol Psychiatr. 1986 ; 137: 151-163
27. Dixon AK, Fisch HU, Huber C, et al. Ethological studies in animals and man: Their use in psychiatry. Pharmacopsychiatry. 1989 ; 22: 44-50
28. Domino EF. History of modern psychopharmacology - a personal view with an emphasis on antidepressants. Psychosom Med. 1999 ; 61: 591-598
29. Dording CM, Mischoulon D, Petersen TJ, et al. The pharmacologic management of SSRI-induced side effects: A survey of psychiatrists. Ann Clin Psychiatry. 2002 ; 14: 143-147
30. Duman CH. Models of depression. Vitam Horm. 2010 ; 82: 1-21
31. Yacoubi M EI, Vaugeois JM. Genetic rodent models of depression. Curr Opin Pharmacol. 2007 ; 7: 3-7
32. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am. 1996 ; 19: 179-200
33. Forbes NF, Stewart CA, Matthews K, et al. Chronic mild stress and sucrose consumption: Validity as a model of depression. Physiol Behav. 1996 ; 60: 1481-1484
34. Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: A patient-level meta-analysis. JAMA. 2010 ; 303: 47-53
35. Garland E, Pettus-Davis C, Howard M. Self-medication among traumatized youth: Structural equation modeling of pathways between trauma history, substance misuse, and psychological distress. J Behav Med. 2012 2012 ;:
36. Geddes J, Carney SM, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: A systematic review. Lancet. 2003 ; 361: 653-661
37. Geddes JR, Freemantle N, Mason J, et al. SSRIs versus other antidepressants for depressive disorder. Cochrane Database Syst Rev. 2000 ; 2 :
38. Goodrich WW. FDA's regulations under the Kefauver-Harris Drug Amendments of 1962. Food Drug Cosmet Law J. 1963 ; 18: 561-569
39. Grant EC, MacKintosh JH. A comparison of the social postures of some common laboratory rodents. Behaviour. 1963 ; 21: 246-259
40. Harmer CJ, Cowen PJ, Goodwin GM. Efficacy markers in depression. J Psychopharm. 2011 ; 25: 1148-1158
41. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960 ; 23: 56-62
42. Hendrie CA, Pickles AR. Depression as an evolutionary adaptation: Implications for the development of preclinical models. Med Hypotheses. 2009 ; 72: 342-347
43. Hendrie CA, Pickles AR. Depression as an evolutionary adaptation: Anatomical organisation around the third ventricle. Med Hypotheses. 2010 ; 74: 735-740
44. Hendrie CA, Starkey NJ. Pairbond disruption in Mongolian gerbils: Effects on subsequent social behaviour. Physiol Behav. 1998 ; 63: 895-901
45. Hendrie CA, Phillips D, Pickles AR. Behavioural scientists appear not to have specialist knowledge of laboratory animal behaviour. J Psychopharm. 2011 ; 25: A35 - A35
46. Hendrie CA, Sarailly J, Starkey NJ. Evidence to suggest that self-medication with alcohol is not an effective treatment for the control of depression. J Psychopharm. 1998 ; 12: 112
47. Hendrie CA, Weiss SM, Eilam D. Exploration and predation models of anxiety: Evidence from laboratory and wild species. Pharmacol Biochem Behav. 1996 ; 54: 13-20
48. Herrling PL. The drug discovery process. Prog Drug Res. 2005 ; 62: 1-14
49. Hindmarch I. Expanding the horizons of depression: Expanding the monoamine hypothesis. Hum Psychopharm Clin Exp. 2001 ; 16: 203-218
50. Hollon SD, Thase ME, Markowitz JC. Treatment and prevention of depression. Psychol Sci Public Interest. 2002 ; 3: 39-77
51. Holmes A, Parmigiani S, Ferrari PF, et al. Behavioral profile of wild mice in the elevated plus-maze test for anxiety. Physiol Behav. 2000 ; 71: 509-516
52. Hughes S, Cohen D. A systematic review of long-term studies of drug treated and non-drug treated depression. J Affect Disord. 2009 ; 118: 9-18
53. Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviours. JAMA. 2004 ; 292: 338-343
54. Keeney AJ, Hogg S. Behavioural consequences of repeated social defeat in the mouse: Preliminary evaluation of a potential animal model of depression. Behav Pharmacol. 1999 ; 10: 753-764
55. Kelly P, Wrynn AS, Leonard BE. The olfactory bulbectomized rat as a model of depression: An update. Pharmacol Ther. 1997 ; 74: 299-316
56. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature. 2008 ; 455: 894-902
57. Krishnan V, Nestler EJ. Animal models of depression: molecular perspectives. Curr Topics Behav Neurosci. 2011 ; 7: 121-147
58. Kudryavtseva NN, Bakshtanovskaya IV, Koryakina LA. Social model of depression in mice of C57BL/6J strain. Pharmacol Biochem Behav. 1991 ; 38: 315-320
59. Lacasse JR, Leo J. Serotonin and depression: A disconnect between the advertisements and the scientific literature. PLoS Med. 2005 ; 2 (12). e392
60. Leo J, Lacasse JR. The media and the chemical imbalance theory of depression. Society. 2008 ; 45: 35-45
61. Lin H-C, Erickson SR, Balkrishnan R. Antidepressant utilization, adherence, and health care spending in the United States: The case of MDD patients 2000-2007. Health Outcomes Res Med. 2011 ; 2: e79 - e89
62. Lipsky MS, Sharp LK. From idea to market: The drug approval process. J Am Board Fam Pract. 2001 ; 14: 362-367
63. Loomer HP, Saunders JC, Kline NS. A clinical and pharmacodynamic evaluation of iproniazid as a psychic energizer. Psychiatr Res Rep Am Psychiatr Assoc. 1957 ; 8: 129-141
64. McArthur R, Borsini F. Animal models of depression in drug discovery: A historical perspective. Pharm Biochem Behav. 2006 ; 84: 436-452
65. Micó JA, Ardid D, Berrocoso E, et al. Antidepressants and pain. Trends Pharmacol Sci. 2006 ; 27: 348-354
66. Middleton H, Shaw I, Feder G. NICE guidelines for the management of depression are clear for severe depression, but uncertain for mild or moderate depression. BMJ. 2005 ; 330: 267-268
67. Miller G. Is pharma running out of brainy ideas?. Science. 2010 ; 329: 502-504
68. Mojtabai R, Olfson M. Proportion of antidepressants prescribed without a psychiatric diagnosis is growing. Health Aff (Millwood). 2011 ; 30: 1434-1442
69. Möller HJ, Volz HP. Drug treatment of depression in the 1990s. An overview of achievements and future possibilities. Drugs. 1996 ; 52: 625-638
70. Moncrieff J. Are antidepressants as effective as claimed? No, they are not effective at all. Can J Psychiatry. 2007 ; 52: 96-97
71. Monleon S, D'Aquila P, Parra A, et al. Attenuation of sucrose consumption in mice by chronic mild stress and its restoration by imipramine. Psychopharmacology. 1995 ; 117: 453-457
72. Morgan CJA, Curran HV. Ketamine use: A review. Addiction. 2012 ; 107: 27-38
73. Nestler EJ, Hyman SE. Animal models of neuropsychiatric disorders. Nat Neurosci. 2010 ; 13: 1161-1169
74. Depression: Management of Depression in Primary and Secondary Care. Clinical Guideline 23. London: National Institute for Clinical Excellence ; 2004 :
75. Nutt D, Goodwin G. ECNP Summit on the future of CNS drug research in Europe 2011: Report prepared for ECNP by David Nutt and Guy Goodwin. Eur Neuropsychopharmacol. 2011 ; 21: 495-499
76. Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharm. 2009 ; 19: 34-40
77. Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nature Rev Drug Discov. 2010 ; 9: 203-214
78. Pickles AR, Hagan JJ, Jones DNC, et al. Short-term individual housing induced social deficits in female Mongolian gerbils: Attenuation by chronic but not acute imipramine. Neuropharmacology. 2012 ; 62: 1993-1998
79. Pigott HE, Leventhal AM, Alter GS, et al. Efficacy and effectiveness of antidepressants: Current status of research. Psychother Psychosom. 2010 ; 79: 267-279
80. Porsolt R, Brossard G, Hautbois C, et al Current Protocols in Neuroscience. John Wiley & Sons, Inc. ; 2001: 8.10A.1-10.
81. Porsolt R, Le Pichon M, Jalfre M. Depression: A new animal model sensitive to antidepressant treatments. Nature. 1977 ; 266: 730-732
82. Rodgers RJ, Hendrie CA. Agonistic behaviour in rats: Evidence for non-involvement of opioid mechanisms. Physiol Behav. 1982 ; 29: 85-90
83. Rodgers RJ, Hendrie CA. Social conflict activates status-dependent endogenous analgesic or hyperalgesic mechanisms in male mice: Effects of naloxone on nociception and behaviour. Physiol Behav. 1983 ; 30: 775-780
84. Rodgers RJ, Hendrie CA, Waters AJ. Naloxone partially antagonizes post-encounter analgesia and enhances defensive responding in male rats exposed to attack from lactating conspecifics. Physiol Behav. 1983 ; 30: 781-786
85. Rygula R, Abumaria N, Flugge G, et al. Anhedonia and motivational deficits in rats: Impact of chronic social stress. Behav Brain Res. 2005 ; 162: 127-134
86. Samuels BA, Leonardo ED, Gadient R, et al. Modeling treatment-resistant depression. Neuropharmacology. 2011 ; 61: 408-413
87. Siegfried B, Frischknecht HR, Riggio G, et al. Long-term analgesic reaction in attacked mice. Behav Neurosci. 1987 ; 101: 797-805
88. Skolnick P. Antidepressants for the new millennium. Eur J Pharmacol. 1999 ; 375: 31-40
89. Smolinksy A, Bergner C, LaPorte J, et al Mood and Anxiety Related Phenotypes in Mice. Neuromethods 42. Gould TD, ed. New York: Humana Press ; 2009: 21-36.
90. Song C, Leonard BE. The olfactory bulbectomised rat as a model of depression. Neurosci Biobehav Rev. 2005 ; 29: 627-647
91. Steru L, Chermat R, Thierry B, et al. The tail suspension test: A new method for screening antidepressants in mice. Psychopharmacology (Berl). 1985 ; 85: 367-370
92. Tinbergen N. On aims and methods of ethology. Zeitschrift fur Tierpsychologie. 1963 ; 20: 410-433
93. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Am J Psychiatry. 2006 ; 163: 28-40
94. Troisi A. Ethological research in clinical psychiatry: The study of nonverbal behavior during interviews. Neurosci Biobehav Rev. 1999 ; 23: 905-913
95. Troisi A, Pasini A, Bersani G, et al. Ethological assessment of the DSM-III subtyping of unipolar depression. Acta Psychiatr Scand. 1990 ; 81: 560-564
96. Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent effcacy. N Engl J Med. 2008 ; 358: 252-256
97. Üstün TB, Ayuso-Mateos JL, Chatterji S, et al. Global burden of depressive disorders in the year 2000. Br J Psychiatry. 2004 ; 184: 386-392
98. Van Praag HM. Biological psychiatry: Still marching forward in a dead end. World Psychiatry. 2010 ; 9: 164-165
99. Van Praag HM, Kahn RS, Asnis GM. Denosologization of biological psychiatry or the specificity of 5-HT disturbances in psychiatric disorders. J Affect Disord. 1987 ; 13: 1-8
100. Varty GB, Cohen-Williams ME, Hunter JC. The antidepressant-like effects of neurokinin NK1 receptor antagonists in a gerbil tail suspension test. Behav Pharmacol. 2003 ; 14: 87-95
101. Verkman AS. Drug discovery in academia. Am J Physiol Cell Physiol. 2004 ; 286: C465 - C474
102. Walsh BT, Seidman SN, Sysko R, et al. Placebo response in studies of major depression: Variable, substantial, and growing. JAMA. 2002 ; 287: 1840-1847
103. Wattiez A-S, Libert F, Privat A-M, et al. Evidence for a differential opioidergic involvement in the analgesic effect of antidepressants: Prediction for efficacy in animal models of neuropathic pain?. Br J Pharmacol. 2011 ; 163: 792-803
104. West AP. Neurobehavioral studies of forced swimming: the role of learning and memory in the forced swim test. Prog Neuropsychopharmacol Biol Psychiatry. 1990 ; 14: 863-877
105. Willner P. The validity of animal models of depression. Psychopharmacology. 1984 ; 83: 1-16
106. Willner P. Validity, reliability and utility of the chronic mild stress model of depression: A 10-year review and evaluation. Psychopharmacology. 1997 ; 134: 319-329
107. Willner P, Towell A, Sampson D, et al. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology. 1987 ; 93: 358-364
108. Wong ML, Licinio J. From monoamines to genomic targets: A paradigm shift for drug discovery in depression. Nat Rev Drug Discov. 2004 ; 3: 136-151
109. Woodcock J, Woosley R. The FDA Critical Path Initiative and its influence on new drug development. Ann Rev Med. 2008 ; 59: 1-12
110. The World Health Report 2002: Reducing Risks, Promoting Healthy Life. Geneva, Switzerland: World Health Organization ; 2002 :
111. Yalcin I, Aksu F, Belzung C. Effects of desipramine and tramadol in a chronic mild stress model in mice are altered by yohimbine but not by pindolol. Eur J Pharmacol. 2005 ; 514: 165-174
112. Cryan JF, Holmes A. The ascent of mouse: Advances in modelling human depression and anxiety. Nat Rev Drug Discov. 2005 ; 4: 775-790
113. Mendl M, Burman OH, Paul ES. An integrative and functional framework for the study of animal emotion and mood. Proc Biol Sci. 2010 ; 277: 2895-2904
114. Pringle A, Browning M, Cowen PJ, et al. A cognitive neuropsychological model of antidepressant drug action. Prog Neuropsychopharmacol Biol Psychiatry. 2011 ; 35: 1586-1592
115. Cryan JF, Holmes A. The ascent of mouse: Advances in modelling human depression and anxiety. Nat Rev Drug Discov. 2005 ; 4: 785-790
116. Hendrie CA, Pickles AR. Depression as an evolutionary adaptation: Anatomical organisation around the third ventricle. Med Hypotheses. 2010 ; 74: 735-740
117. Markou A, Chimmulera C, Geyer MA, et al. Removing obstacles in neuroscience drug discovery: The future path for animal models. Neuropsychopharmacology. 2009 ; 34: 74-89
118. Price J, Sloman L, Gardner R, et al. The social competition hypothesis of depression. Br J Psychiatry. 1998 ; 164: 309-315
119. Willner P. The validity of animal models of depression. Psychopharmacology. 1984 ; 83: 1-16
120. Willner P, Mitchell PJ. The validity of animal models of predisposition to depression. Behav Pharmacol. 2002 ; 13: 169-188